bempedoic acid

This medicine is authorised for use in the European Union.


Nilemdo is a medicine for lowering levels of cholesterol in the blood.

It is used in patients with primary hypercholesterolaemia or mixed dyslipidaemia (conditions that cause high levels of fats, including cholesterol, in the blood). Patients taking the medicine are required to be on a low-fat diet.

Nilemdo is used in combination with a statin, with or without other fat-lowering medicines, in patients whose cholesterol levels are not lowered enough by the maximum dose of a statin. Nilemdo can also be used alone or in combination with other fat-lowering medicines in patients who cannot take statins.

Nilemdo contains the active substance bempedoic acid.

This EPAR was last updated on 08/04/2022

Authorisation details

Product details
Agency product number
Active substance
Bempedoic acid
International non-proprietary name (INN) or common name
bempedoic acid
Therapeutic area (MeSH)
  • Hypercholesterolemia
  • Dyslipidemias
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Daiichi Sankyo Europe GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Zielstattstrasse 48
81379 Munich

Product information

01/04/2022 Nilemdo - EMEA/H/C/004958 - IB/0023

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Lipid modifying agents

Therapeutic indication

Nilemdo is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL C goals with the maximum tolerated dose of a statin (see sections 4.2, 4.3, and 4.4) or,
  • alone or in combination with other lipid-lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated.

Assessment history

How useful was this page?

Add your rating
2 ratings
2 ratings
2 ratings